A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

Phase I ◽

Multicenter Study ◽

Single Agent ◽

First Line ◽

First Line Therapy ◽

Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study

Journal of Gastroenterology and Hepatology ◽

10.1111/jgh.12542 ◽

2014 ◽

Vol 29 (7) ◽

pp. 1463-1469 ◽

Cited By ~ 18

Author(s):

Sangheun Lee ◽

Beom Kyung Kim ◽

Seung Up Kim ◽

Soo Young Park ◽

Ja Kyung Kim ◽

...

Keyword(s):

Prognostic Factors ◽

Clinical Outcomes ◽

Multicenter Study ◽

First Line ◽

First Line Therapy ◽

Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy

Future Oncology ◽

10.2217/fon-2020-0986 ◽

2021 ◽

Vol 17 (7) ◽

pp. 755-757 ◽

Cited By ~ 1

Author(s):

Alessandro Rizzo ◽

Angela Dalia Ricci ◽

Giovanni Brandi

Keyword(s):

First Line ◽

First Line Therapy ◽

Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

Journal of Hepatology ◽

10.1016/j.jhep.2011.07.033 ◽

2012 ◽

Vol 56 (2) ◽

pp. 486-487 ◽

Cited By ~ 6

Author(s):

Jairo A. Garcia ◽

Lewis R. Roberts

Keyword(s):

Phase Ii ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

First Line Therapy ◽

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00050-9 ◽

2015 ◽

Vol 16 (7) ◽

pp. 859-870 ◽

Cited By ~ 344

Author(s):

Andrew X Zhu ◽

Joon Oh Park ◽

Baek-Yeol Ryoo ◽

Chia-Jui Yen ◽

Ronnie Poon ◽

...

Keyword(s):

Line Treatment ◽

Second Line ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

First Line Therapy ◽

170P Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)

Annals of Oncology ◽

10.1016/j.annonc.2020.10.191 ◽

2020 ◽

Vol 31 ◽

pp. S1305

Author(s):

X. Chen ◽

W. Li ◽

X. Wu ◽

F. Zhao ◽

H. Wu ◽

...

Keyword(s):

First Line ◽

First Line Therapy ◽

Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25]

European Journal of Cancer ◽

10.1016/j.ejca.2018.06.002 ◽

2018 ◽

Vol 100 ◽

pp. 135-136

Author(s):

Ian Chau ◽

Markus Peck-Radosavljevic ◽

Christophe Borg ◽

Peter Malfertheiner ◽

Jean Francois Seitz ◽

...

Keyword(s):

Phase Iii ◽

Line Treatment ◽

Second Line ◽

First Line ◽

First Line Therapy ◽

Hepatic reserve and the other conditions for regorafenib as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib in Japanese practical setting

Annals of Oncology ◽

10.1093/annonc/mdx660.047 ◽

2017 ◽

Vol 28 ◽

pp. x71

Author(s):

T. Terashima ◽

T. Yamashita ◽

K. Arai ◽

S. Kaneko

Keyword(s):

The Other ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Hepatic Reserve ◽

First Line Therapy ◽

Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study

Oncology ◽

10.1159/000350841 ◽

2013 ◽

Vol 85 (1) ◽

pp. 44-52 ◽

Cited By ~ 33

Author(s):

Chih-Hung Hsu ◽

Yoon Koo Kang ◽

Tsai-Shen Yang ◽

Chia-Tung Shun ◽

Yu-Yun Shao ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

First Line Therapy ◽

Asian Patients ◽

Multicenter Phase ◽

Faculty of 1000 evaluation for Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718087038.793483841 ◽

2013 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Phase Iii ◽

First Line ◽

First Line Therapy ◽

O-005 Ramucirumab (RAM) as second-Line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: comprehensive results from the randomized phase III REACH study

Annals of Oncology ◽

10.1093/annonc/mdv235.04 ◽

2015 ◽

Vol 26 ◽

pp. iv109

Author(s):

A. Zhu ◽

M. Kudo ◽

J.O. Park ◽

B.-Y. Ryoo ◽

C.-J. Yen ◽

...

Keyword(s):

Phase Iii ◽

Line Treatment ◽

Second Line ◽

First Line ◽

First Line Therapy ◽